Shares in the market heavyweight plummeted by over 10% at one point during early trading on Tuesday following the failure of a trial into a drug for a muscle disorder.
Novartis shares plummet following yet another clinical trial setback
Keystone-SDA
A black day for investors in the Swiss pharmaceutical group Novartis: shares in the market heavyweight plummeted by over 10% at one point during early trading on Tuesday following the failure of a trial into a drug for a muscle disorder.
This content was published on
September 8, 2026 - 13:58
Pharma major Novartis falls 10% after three drug trial setbacks
Novartis secoué en bourse après une succession d’échecs cliniques - Le Temps
Novartis del-desiran drug trial fails, stock drops 9%
Novartis verliert 24 Milliarden Börsenwert nach Medikamenten-Rückschlägen
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
Nach Studienfehlschlägen: Aktien von Novartis stehen vor Bewährungsprobe
A Zurigo affonda Novartis, nuovo flop su farmaco muscolare sperimentale
Tercer revés para Novartis en pocos días: la farmacéutica se derrumba en Bolsa tras los malos resultados de un medicamento muscular
Major Novartis shareholder calls for board shake-up after drug trial setbacks
Novartis erleidet weiteren Rückschlag in der Forschung. Aktie verliert über 10 Prozent
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Le géant pharmaceutique bâlois a reconnu mardi qu’un traitement en cours d’étude contre une maladie neuromusculaire n’avait pas…
The HARBOR study failure is Novartis's second major late-stage trial setback in days and its third pipeline blow in a week
Novartis aus Basel verliert 24 Milliarden Franken an Börsenwert nach Misserfolgen bei zwei wichtigen Medikamenten. Aktien fallen…
(Bloomberg) -- Novartis AG suffered its third clinical-trial setback in a week after a treatment for a rare muscle-wasting…
Novartis' del-desiran misses HARBOR trial's primary endpoint, adding to pelacarsen miss and CAR-T deaths; shares sink 10%.
